Inactivation of p53 has been shown to correlate with drug resistance in tumors. However, in clear cell renal cell carcinoma (ccRCC), p53 is rarely mutated, yet the tumors remain highly insensitive to the conventional chemotherapeutic drugs. The underlying mechanisms responsible for the non-genetic p53 inactivation remain obscure. Here, we report, for the first time, that Apoptosis Stimulating of P53 Protein 1 (ASPP1) was remarkably downregulated at both mRNA (about 3.9-fold) and protein (about 4.9-fold) levels in ccRCC human specimens in comparison with the paired normal controls. In addition, lower ASPP1 was closely related to the higher grade of tumors and shorter life expectancy of ccRCC patients, both with p < 0.001. We also find that CpG island hypermethylation at promoter region contributed to the suppression of ASPP1 expression in ccRCC that contained relatively low levels of ASPP1. Further functional studies demonstrated that forced expression ASPP1 not only significantly inhibited the growth rate of ccRCC, but also promoted sensitivity of ccRCC to the conventional chemotherapeutic drug 5-fluorouracil (5-FU)-induced apoptosis. Moreover, ASPP1 expression was accompanied with the apoptosis-prone alterations of p53 targets expression and p53 target PIG3 luciferase reporter activation. In contrast, ASPP1 knockdown promoted cell growth and prevent 5-FU-induced p53 activation and apoptosis. In conclusion, our results suggest that ASPP1 silencing is one of dominate mechanisms in inhibiting wild type p53 in ccRCC. ASPP1, therefore, may be potentially used as a promising biomarker for prognosis and therapeutic intervention in ccRCC.
Introduction
Renal cell carcinoma (RCC) is the second most common cancer in the urological system and accounts for approximately 3% of malignant neoplasms worldwide. 1 Clear cell RCC (ccRCC) represents the most common (75-80%) and the most lethal histologic subtype of RCC. 2 To date, surgery remains the only possible curative therapy for patients with localized ccRCC. Nevertheless, about one in third patients were diagnosed with distal metastasis and up to 30% of patients relapse after potential curative surgery. 3, 4 Once advanced diseases occur, there is no effective treatment, because ccRCC is notorious for its nature of highly resistance to the conventional DNA-damaging therapies, including radiotherapy and chemotherapy. 5, 6 So, the major obstacle for ccRCC management is to identify effective early prognostic markers and therapeutic targets either for single or for the combined treatment strategies.
p53 is the most extensively studied tumor suppressor, which can be elevated in response to DNA damage and oncogenesis stresses. 7 Accumulated p53 can lead to cell cycle arrest allowing damaged DNA repair or apoptosis to eliminate abnormal cells. 8, 9 p53 activation is particularly critical for the maintenance of genomic stability and chemotherapeutic drug-induced apoptosis. [9] [10] [11] It is thus not surprising that impairment of wild type p53, more frequently by a point missense mutation, is closely relevant to oncogenesis, malignancy progression and/or drug resistance. 11 However, despite a high mutation rate reported in human cancers (about 50%), p53 is rarely mutate in ccRCC. 12 It remains an open question how cells circumvent the activation of wild type p53 and gain drug resistance phenotype in ccRCC. One potential explanation is that certain unknown dominant mechanisms may exist to inhibit wild type p53's activities. In support of this idea, murine double minute2 (MDM2), an E3 ligase targeting p53 for degradation, is increased in ccRCC and positively associated with poor prognosis. 13, 14 MDM-2 inhibitor, nutlin-3, can successfully induce p53 stabilization and accumulation. However, enhanced p53 leads to cell cycle arrest or senescence, but not apoptosis, [15] [16] [17] which suggest that the regulatory mechanisms of p53-dependent apoptotic machinery are particularly impaired in ccRCC. Notably, inducing apoptosis is an ideal way for chemotherapeutic drugs to remove cancers, it is thus critical for us to understand the non-genetic inactivation mechanisms of p53, particularly p53-dependent apoptosis in ccRCC.
ASPP1 is one of such candidates in regulating p53-dependent apoptosis. ASPP1 belongs to Apoptotic Stimulating of p53 Protein (ASPP) family that is characterized by the conserved C-terminal domains of ankyrin repeats, SH3 and proline-rich domain. [18] [19] [20] ASPP1 and another ASPP member, ASPP2, can directly interact with p53 or its family members, p63 and p73, and selectively promote their transcriptional activity toward pro-apoptotic genes, without obvious impact on the cell cycle arrest genes. 19, [21] [22] [23] It is possible that ASPP1 may be such a protein, whose deregulation contributes to the inactivation of wild type p53 in human cancers. Indeed, downregulation of ASPP1 has been found in several cancers particularly in those with lower mutation rate of p53, such as breast cancers, 19, 24 hepatocellular carcinoma 25 and leukemia. 26 Nevertheless, the roles of ASPP1 in ccRCC remain completely unknown.
Furthermore, compared to its molecular mechanisms and biological functions, much less is known about the underlying mechanisms of ASPP1 downregulation in cancers. Tumor suppressors suppressed by epigenetic regulation has been well recognized as one of major mechanisms to induce oncogenesis and likely occurs at very early stages of oncogenesis of multiple cancers, including RCC. 27, 28 This leads us to address whether ASPP1 is suppressed and whether it is suppressed by epigenetic mechanisms, such as promoter hypermethylation, in the context of ccRCC.
Therefore, in our study, we analyzed the expression of ASPP1 in ccRCC and also investigated the mechanisms underlying ASPP1 suppression by examining methylation status of ASPP1 promoter CpG islands both in vivo and in vitro. Moreover, the biological functions of ASPP1 on cell growth, p53 activity and drug resistance were further investigated.
Materials and Methods

Patients and tissues
Twenty ccRCC tissues and their corresponding nearby non tumorous tissues were obtained from the First Affiliated Hospital of Harbin Medical University, China, with the approval of the Local Research Ethics Committee. Human renal cell carcinoma tissue array (KD2085) containing 86 cases of ccRCC, 5 cases of sarcomatoid renal cell carcinoma, 3 cases of papillary renal cell carcinoma and 13 cases of normal tissues were purchased from US Biomax, Inc. (Alenabio, Xian, China).
Cell culture and drug treatment
RCC cell lines (786-O, 769-P and CAKI-1) were purchased from ATCC and characterized by Genetic Testing Biotechnology Corporation (Suzhou, China) using short tandem repeat (STR) markers. CCF-RC1 29 was purchased from Shanghai cell bank of Chinese academy of science, China. Cell lines were cultured in RPMI-1640 medium (C11875500BT, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, 04-001-1 A-ACS, Biological Industries, Beit-Haemek, Israel) incubated at 378C in an atmosphere of 5% CO 2 . The human embryonic kidney cell line (HEK293) was cultured in Dulbecco modified Eagle medium (DMEM, C11995500BT, Gibco, Carlsbad, CA, USA) under the same conditions. RCC cells were plated What's new? p53 mutation is rarely detected in ccRCC, but these tumors are highly resistant to chemotherapies. Here, the authors found that ASPP1 suppression is significantly associated with higher grade and poorer survival of ccRCC. Restore ASPP1 inhibits ccRCC proliferation, and also improves ccRCC's sensitivity to the conventional chemotherapeutic drug 5-FU via specifically activating p53's transcriptional activities toward apoptosis. The findings provide insight into the capability of ASPP1 for overcoming ccRCC resistance by re-activating p53-dependent pro-apoptosis activity.
in 24-well plate and treated with different concentrations (0, 2.5, 5 and 10 lg/ml) of 5-Aza-2 0 dC (A3656, Sigma, St. Louis, MO, USA) for 3 days. Cells were then harvested. The mRNA were extracted and subjected to real-time quantitative RT-PCR analysis of ASPP1. The genomic DNA from cells in the presence or absence of 10 lg/ml 5-Aza-2 0 dC, by which ASPP1 transcription was significantly elevated, were further analyzed by a BSP assay. Data were generated from three independent replicates.
RNA extraction and quantitative RT-PCR
Total RNA was isolated from RCC cell lines/tissue samples and paired adjacent normal controls with Trizol (15596018, Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Total RNA (1 lg) was reversely transcribed using a PrimeScript reverse transcription (RT) reagent kit with gDNA Eraser. cDNA synthesis was carried out following the kit protocol. RT reaction was performed for 15 min at 378C, then at 858C for 5 sec, and finally kept at 48C. After that, the cDNA was diluted 10-fold and performed the quantitative RT-PCR using SYBR Premix Ex Tag II (RR820A, Takara, Dalian, China). The conditions as following were used, including 958C for 30 sec, 40 cycles of 958C for 5 sec, 588C for 34 sec and last stage at 958C for 15 sec, 608C for 1 min, 958C for 15 sec by using an applied Biosystems 7500 realtime PCR system. mRNA levels were calculated according to the cycle threshold (Ct) value. The housekeeping gene GAPDH was used as an internal control. The primer sequences used in our study are listed below: ASPP1 Forward 5 0 -GCCAAGGAACAGCGT TTACA-3 0 ; Reverse 5 0 -GCAGA CAGATTGCCGTTCAT-3 0 ; GAPDH Forward 5 0 -CGACCAC TTTGTCAAGCTCA-3 0 ; Reverse 5 0 -ACTGAGTGTGGCAGG GACTC-3 0 .
Immunohistochemistry
The tissue microarray was subjected to antigen retrieval by boiling in 0.01 mol/L citrate buffer for 5 min. Slides were then incubated with the predicted primary antibody ASPP1 (A4355, Sigma-Aldrich, 1 : 100) at room temperature for 1 hr (h). Detection took place by the REAL EnVision detection system (Dako, Glostrup, Denmark) with diaminobenzidine peroxidase serving as chromogen. The slides were briefly counterstained with hematoxylin and mounted. The staining was captured under the same conditions and the intensity was evaluated with a 3-tier grading system (negative or weak, moderate and strong staining intensity).
Bisulfite sequencing PCR (BSP)
Genomic DNA was extracted from RCC cell lines or tissues using phenol/chloroform extraction. 1 lg genomic DNA subjected to bisulfite conversion using EZ DNA Methylation-Gold kit (D5005, Zymo Research, Orange County, CA, USA) following the manufacturer's introduction. 3 ll bisulfite-treated DNA was used in semi-nested PCR. The sequences of PCR primers were as follows:
Reverse 5 0 -CTAACACCTACTTCTCCCCCA-3 0 . The first reaction conditions were 948C for 2 min, 32 cycles at 948C for 30 sec, 608C for 30 sec and 728C for 30 sec. The second PCR conditions were 948C for 2 min, 33 cycles at 948C for 30 sec, 608C for 30 sec and 728C for 30 sec. The final extension was at 728C for 2 min. The PCR products were separated on a 1.5% agarose gel. The purified PCR products were cloned into PMD-18-T vector (D103A, Takara, Dalian, China) and transformed into DH5a competent cell. Randomly selected five to ten clones of each sample underwent sequencing.
Western blot
The ccRCC cells were washed with 1 3 PBS. Cell lysates were prepared by adding urea buffer (2 M Thiourea, 4%CHAPS, 40 mM Tris-Base, 40 mM DTT, 2% Pharmalyte), followed by incubation on ice and vortex shaking for 30 min. Then, the supernatants were collected after 30 min centrifugation at 48C by 16,000 g. The samples were mixed with 5 3 loading buffer and boiled at 1008C for 5 min. Equal amount of proteins were separated at sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to PVDF membranes using the cold transfer buffer. Membranes were blocked with 5% non-fat milk in TBS-T for 1 hr at RT, and subjected to corresponding primary antibody incubation at 48C overnight. Primary antibodies used were listed as below: ASPP1 (A4355, SigmaAldrich), b-actin (66009, Proteintech, Chicago, IL, USA), Bax (A0207, ABclonal, Boston, MA, USA), Bcl-2 (A0207, ABclonal, Boston, MA, USA) and b-tubulin (10094, Proteintech), which were used at a dilution rate of 1:1,000. Secondary antibodies of goat anti-mouse-HRP (ab7046, Abcam, Cambridge, UK) and goat anti-rabbit-HRP (ab6721, Abcam, Cambridge, UK) were diluted at 1:2,000. Signals were visualized by ECL. Membrane was then ready for scanning by Image studio system. Protein quantification was conducted by image J software. The gray values of protein were achieved as gray level of protein band/gray level of loading control.
MTT
Cell proliferation was detected by the colorimetric MTT assay. ccRCC cell lines were plated in 96-well plates and treated with 5-FU at final concentrations of 0, 1.25, 2.5, 5, 10 or 20 lM. After 72 hr incubation, cells were treated with MTT solution at the concentration of 5 mg/ml for 4 hr at 378C. The MTT was discarded carefully and the formazan was dissolved with 100 ll dimethylsulfoxide (0231, DMSO, Amresco Solon, OH, USA). Finally, the absorbance at 490 nm was determined. Each experiment was repeated three times.
Soft agar assay
Base agar was prepared by melting 1% agar (DNA grade) in a microwave and then cooling it to 408C in a water bath. Meanwhile, 2 3 RPMI-1640, supplied with 20% FBS, was warmed up to 408C. After the temperature was equilibrated, the same volume of 1% agar and 2 3 RPMI-1640 was mixed together to give a final concentration of 0.5% agar in 1 3 RPMI-1640. 2 ml of this 0.5% agar was plated in 6-well plates, and the dish rotated until it was completely covered. Top agar, at a final concentration of 0.35%, was prepared in the same way. Cells were trypsinized and counted, before resuspension in 0.35% agar solution at a final concentration of 1,000 per 1.5 ml. Cell suspension (1.5 ml) was then plated on the top of the solidified base agar. Complete medium (2 ml) was added and refreshed every 3-4 days. The experiments were conducted in triplicate. Plates were incubated for 2 weeks at 378C in a 5% CO 2 humidified atmosphere. Cell colonies were visualized following a 3 hr stain with 0.005% crystal violet and examined with a microscope. The colony number in each well was represented by the mean value of the colony numbers examined in 3 randomly chosen microscope fields. The colony numbers for cells were determined by the mean value of the triplicate wells. Standard deviation (SD) was calculated to demonstrate the variation of the experiments.
Xenografted tumor model in vivo
The female nude mice between 4 and 5 weeks were purchased from Beijing HFK Bioscience Co. (Beijing, China), Ltd. 769-P cells were transfected with siRNA scramble control or siRNA specifically targeting ASPP1 using Lipofectamine 2000 (1734972, Invitrogen). siRNA oligos were synthesized by GenePharm Co., Ltd., Suzhou, China. The sequences of siRNA targeting ASPP1 were as follows: ASPP1-1: 5 0 -GCUCAUGGAAGAUC CAAAU-3 0 , ASPP1-2: 5 0 -GCACACAGCGCCUUAAAU A-3 0 . After 72 hr, the ASPP1 expression levels were determined by western blot. Both 769-P cell models were calculated and transplanted subcutaneously into either side of flank of the same female nude mouse with the same cell numbers (5 3 10 6 ). Five mice were used. The tumor volumes were measured every week and calculated as length 3 width 2 3 0.5. After 6 weeks, the mice were euthanized, and the tumor were carefully removed, photographed and weighed. Similar protocol was also applied to 786-O/Vector and 786-O/ASPP1 xenograft models.
Apoptosis assay
769-P and CAKI-1 cells were cultured in 24-well plate and transfected with either siRNA scramble control or siRNA specifically targeting ASPP1 allowing cells growing for 72 hr to knock down ASPP1. 293 T cells were used to pack lentivirus. Briefly, 293 T cells were transfected with FT106-vector-GFP or FT106-ASPP1-GFP lentivirus plasmid using Lipofectamine 2000 (1734972, Invitrogen) and supernatant was collected after 3 days. 786-O cells were infected with collected supernatant and the stable cells were obtained by fluorescence activated cell sorting (FACS). After treatment with 2.5 lM 5-FU for 72 hr, the apoptosis assay was analyzed by using Annexin V/propidium iodide (PI) double staining kit (AO2001, Sungene, Tianjin, China). According to the manufacturer's instructions, the cells were incubated with 5 ll Annexin V solution for 10 min at RT in the dark. Then, 5 ll PI or 7-AAD was added and incubated for additional 10 min. The cells were then analyzed by FACSCalibur (Becton Dickinson, New York, NJ, USA).
Luciferase assay
The cells were seeded into 24-well plates by 3 3 10 4 cells/ well and then transfected with a plasmid mixture including 15 ng Renilla luciferase and 300 ng PIG3-Report by using Lipofectamine 2000 (1734972, Invitrogen). 48 hr after transfection, the cells were harvested and subjected to an reporter assay by using the Dual Luciferase Reporter Assay system (Promega, Madison, WI), according to manufacturer's introduction. The relative luciferase activities were compared in the control and ASPP1 knockdown cells, after normalized with the Renilla luciferase activities.
Statistical analysis
Statistical analysis was done by GraphPad software, version 5. Kaplan-Meier survival analysis was used to investigate the association between ASPP1 expression and ccRCC patient survival. Correlations were calculated according to Spearmen or Pearson correlation. Data are presented as the means 6 standard deviation. Student's t-test was applied to assess the statistical significance of the differences between genetic modified cell models. p Values <0.05 were considered significant.
Results
ASPP1 is downregulated in ccRCC
To understand the role of ASPP1 in ccRCC, we first evaluated the expression of ASPP1 in 20 ccRCC patients' tumor samples and their matched adjacent normal controls. Our results showed that the average mRNA transcripts and proteins of ASPP1 were significantly decreased by 3.9-and 4.9-fold, respectively, in ccRCC tissues compared to the paired normal controls (p < 0.01, Figs. 1a-1c) , suggesting ASPP1 may play a role in inhibiting ccRCC development. The Tumor Node Metastasis (TNM)-stage is a wildly accepted cancer staging system used for solid tumors. 30 To further understand whether the downregulation of ASPP1 is involved in ccRCC progression, an immunohistochemistry assay was employed in 13 normal kidney tissues and 86 ccRCC tissues of different TNM stages. As shown in Figure 1d , ASPP1 exclusively expressed in the renal tubule epithelial cells, with a much stronger staining in the distal convoluted tubules than that in the proximal convoluted tubule cells. In comparison with the normal controls, ASPP1 was remarkably decreased in 95.3% of the patients (81 out of 86) with ccRCC (p < 0.0001, Figs. 1d and 1e and Table 1 ). Importantly, although it had no significant correlation with pathological characterizations, such as age and sex, decreased ASPP1 protein was significantly associated with higher TNM-stage of ccRCC (r 5 20.3223, p < 0.0001, Table 1 ). Supportively, a negative association between ASPP1 transcript and TNM-stages were also obtained by analyzing RNA-seq results of ASPP1 in 481 ccRCC from TCGA database (p < 0.001, Fig. 1f ). In addition, when using medium value of ASPP1 transcripts as a threshold, patients with lower ASPP1 had a shorter life expectancy than those with higher ASPP1 (p 5 0.00033, Fig. 1g ). These data together suggest that ASPP1 suppression might contribute to ccRCC pathological progression and it could be a potential prognostic factor for ccRCC.
It is also worthy of note that despite a small number of cases involved, a significant reduction of ASPP1 was also observed in other RCC pathological subtypes, such as sarcomatoid renal cell carcinoma (five cases involved) and papillary renal cell carcinoma (three cases involved) (Supporting Information Fig. 1) , which indicate that the downregulation of ASPP1 may be a common mechanism generally involved in RCC development.
Promoter hypermethylation contributes to ASPP1 silencing in ccRCC
We then explored the potential mechanisms that contribute to ASPP1 silencing in ccRCC. 769-P, CAKI-1, CCF-RC1 and 786-O are well defined ccRCC cell lines. Consistent with the in vivo data described above, ASPP1 was significantly decreased in these cancer cell lines at both mRNA and protein levels in comparison with HEK293 normal kidney controls (p < 0.01, Figs. 2a and 2b) . In addition, cell lines with lower ASPP1 mRNA transcripts tended to express lower amount of ASPP1 protein (Figs. 2a and 2b) . Further quantification and correlation analysis showed that the proteins levels was positively associated with mRNA levels of ASPP1 with an r value 0.9571 (p < 0.01, Fig. 2c) , suggesting that the regulation at transcriptional level may be a major mechanism to inhibit ASPP1 protein expression. Given that hypermethylation of CpG islands in the promoter regions is a well-established mechanism to inhibit tumor suppressor genes through modulating mRNA transcripts in cancers, we then treated ccRCC cells with 5-Aza-2 0 -deoxycytidine (5-Aza-2 0 dC), an effective DNA methylation inhibitor, to explore the resultant effects on ASPP1 transcripts. In 786-O, CCF-RC1 and CAKI-1 cells, the transcription of ASPP1 was restored by 5-Aza-2 0 dC treatment and ASPP1 mRNA was significantly increased in a 5-Aza-2 0 dC concentration dependent manner (Fig. 2d) . However, 769-P, which contained relatively high ASPP1, was tolerated to the treatment (Fig. 2d) . These data indicate that promoter hypermethylation may be one of major mechanisms to inhibit ASPP1 transcription particularly in those ccRCC cells with relative low levels of ASPP1.
To further verify that ASPP1 can be regulated by promoter hypermethylation, we applied Bisulfite Sequencing PCR (BSP) techniques to detect the promoter methylation status in the aforementioned cell models. 22 CpG sites spanning ASPP1 promoter from 2590 to 2850 was examined (Fig. 2e) . Our data showed that the methylated CpG was barely detected in HEK293 (11%) and 769-P (8%) (left panels, Fig. 1f ). By contrast, the methylation rate in 786-O, CCF-RC1 and CAKI-1 were 63%, 42% and 39%, respectively, in the same promoter region (left panels, Fig. 2f) . Moreover, the high rates of promoter methylation in 786-O, CCF-RC1 and CAKI-1 were significantly suppressed by approximately three to fourfold (right panels, Fig. 2f ), which was in concert with an increased ASPP1 transcription after the treatment as shown in Figure 2d . These data further suggested that promoter hypermethylation is indeed one of mechanisms to inhibit ASPP1 expression in vitro.
ASPP1 inhibits ccRCC growth both in vitro and in vivo
We next investigated the roles of ASPP1 in regulating cell growth in ccRCC. First of all, ASPP1 was stably overexpressed by lentivirus infection in 786-O, which expresses relative lower endogenous ASPP1. The resulting stable line was named 786-O/ASPP1 (Fig. 3a) . Then the cell viability was measured by a MTT assay. As shown in Figure  3b , 786-O/ASPP1 proliferated slower than lentivirus vector control cells (786-O/Vector) (p < 0.05), suggesting ASPP1 regulates cell proliferation. To confirm the inhibitory effect of ASPP1 in regulating cell growth, a soft agar assay was also applied to 786-O/ASPP1 and 786-O/Vector cells. As expected, the cloning numbers were decreased greater than twofold with ASPP1 expression (Figs. 3c and 3d) .
To provide further evidences, ASPP1 expression was inhibited by using two independent RNAi specifically targeting ASPP1 in 769-P and CAKI-1 cells, two ccRCC cell models with higher ASPP1 levels. As shown in Figure 3e , both ASPP1 specific RNAi significantly reduced ASPP1 expression by 87% in 769-P and 70% in CAKI-1 cells (p < 0.01). The growth rate of 769-P and CAKI-1 was then detected by a MTT assay and soft agar assay. ASPP1 inhibition significantly and consistently enhanced cell growth rate in both cell lines and the difference of cell survival rates became more evident with prolonged incubation duration (p < 0.05 at 24 hr and p < 0.01 at 72 hr, Fig. 3f ). In addition, the cloning numbers were increased greater than twofold with ASPP1 silencing in both 769-P and CAKI-1 cells in a soft agar assay (p < 0.01, Figs. 3g and 3h) . Notably, similar inhibitory effects on cell growth were induced by the two independent RNAi oligos against ASPP1. These data together suggest that ASPP1 inhibits tumor growth of ccRCC in vitro.
The anti-survival capability of ASPP1 was also investigated in vivo by using xenograft mice models. 769-P cells transfected with the same amount of scramble control or ASPP1 RNAi (1 1 2) . The downregulation of ASPP1 was confirmed by western blot with the same batch of cells (Fig. 4a) . To minimize the potential variation generated by individual nude mice, the control and ASPP1 knockdown cells were paired and respectively injected into one nude mouse at symmetrical subcutaneous regions. All tumor-bearing mice had rapidly increasing tumor burdens. However, the mice without ASPP1 inhibition showed an even more markedly increased growth rate as indicated by the tumor volume. The difference in tumor size between the two groups became statistic significant 2 weeks after injection (p < 0.05) and turned more evident over time (p < 0.01, Fig.  4b ). At the end of experiments, the mice were dissected, and the tumor weight was measured immediately. As shown in Figure 4c , the tumor weight was significantly increased by 3.3-fold in ASPP1 knockdown cells compared to control cells (p < 0.01). By contrast, ASPP1 overexpression in 786-O cells significantly inhibited the growth of xenografts, as indicated by both tumor volume and tumor weight (Figs. 4d-4f ). These data together suggested that ASPP1 inhibits ccRCC growth in vivo.
ASPP1 affects ccRCC's sensitivity to 5-fluorouracil (5-FU) by inhibiting p53
Drug resistance is one of major obstacles to treat ccRCC. To provide evidence on the influences of ASPP1 on ccRCC's response to chemotherapy, the cells viability was also measured in the presence and absence of chemotherapeutic drug 5-FU in 786-O overexpressing ASPP1 (786-O/ASPP1) and the vector controls (786-O/Vector). Supportively, 786-O/ ASPP1 was more sensitive to the treatment of 5-FU than 786-O/vector, with twofold difference on IC50 (Fig. 5a ). In contrast, IC50 values were enhanced by about twofold by RNAi-mediated ASPP1 knockdown in 769-P and CAKI-1 cells (Figs. 5b and 5c ), suggesting that ASPP1 enhances ccRCC's sensitivity to 5-FU. Considering induction apoptosis is one of major mechanisms for 5-FU to act, we further investigated ASPP1's proapoptotic effect in response to 5-FU treatment by Annexin V/PI double staining following a FACS assay. As expected, the apoptosis percentage was increased with ASPP1 expression no matter 5-FU was added or not in 786-O cells, although a more evident difference was obtained in the treated groups (p < 0.05, Fig. 5d and Supporting Information Fig. 2a) . In contrast, ASPP1 knockdown apparently contributed, albeit weakly, to reduce apoptosis in the untreated cells (Figs. 5e and 5f and Supporting Information Figs. 2b and 2c ). Apoptosis occurred with 5-FU treatment in both cell lines, as expected. Interestingly, the two independent RNAi oligos against ASPP1 led to similar extents of the inhibitory effects toward 5-FU-induced apoptosis. 5-FU-induced apoptosis reduced by RNAi-mediated ASPP1 inhibition to about 60% that of scramble control treated cells in both 769-P and CAKI-1 (p < 0.05, Figs. 5e and 5f and Supporting Information Figs. 2b and 2c) . These data together suggest that ASPP1 promotes apoptosis. To gain further evidences on the molecular mechanisms of ASPP1-mediated apoptosis, downstream targets and transcriptional activity of p53 were compared between 786-O/ Vector and 786-O/ASPP1. As expected, p53 and its proapoptosis effector Bax were both induced by 5-FU in 786-O/ Vector and 786-O/ASPP1cells. Importantly, ectopic ASPP1 expression (786-O/ASPP1) promoted Bax in the untreated cells and also led to a further induction of Bax in the treated cells. On the contrary, p53 anti-apoptotic effector Bcl-2 was suppressed in 786-O/ASPP1. Unlike Bax/Bcl-2, p21, a representative cell cycle arrest target of p53, was not influenced by ASPP1 expression (Fig. 6a) , suggesting ASPP1 recovery may particularly potentate p53-dependent apoptosis. Supportively, RNAi-mediated ASPP1 knockdown significantly suppressed 5-FU-induced p53 pro-apoptotic effector Bax, while promoted anti-apoptotic effector Bcl-2. However, no obvious reduction of p21 was observed with ASPP1 knockdown (Figs.  6b and 6c) .
We further examined p53's transcriptional activity by a reporter assay. As shown in Figure 6d , 5-FU increased p53 transcriptional activity by approximately fourfold at the proapoptotic PIG3 reporter in 786-O cells. ASPP1 expression promoted p53's transcriptional activity in the untreated cells (1.6 fold, p < 0.05) and led to a further induction by about fivefold after 5-FU treatment (p < 0.01). In support of above finding, p53's transcriptional activity toward PIG3 reporter was significantly reduced by about 50% in 769-P and 70% in CAKI-1 upon ASPP1 silencing (p < 0.01, Figs. 6e and 6f) . These data together suggest that ASPP1 suppression may prevent fully activation of p53 toward apoptosis and therefore confers to the enhanced drug resistance in ccRCC. ASPP1 reconstruction may be a potential strategies to improve ccRCC's response to 5-FU.
Discussion
Bypassing resistance to apoptosis by better understanding the mechanisms of oncogenesis and drug resistance remains an important issue in cancer research. 31 ccRCC is notorious for its native resistance to chemotherapies and a representative model to study dominate mechanisms which regulate wild type p53 in cancers. 5 In our study, we present the first evidence to support the potential tumor suppressor function of ASPP1, a newly identified p53 activator, in ccRCC. Importantly, restoring ASPP1 expression suppresses cell growth and enhances drug sensitivity to 5-FU, which is companied with the activation of wild type p53 in ccRCC. Thus, ASPP1 silencing may be one of dominate mechanisms to inhibit wild type p53 activity and recovering expression of ASPP1 is a potential treatment for ccRCC. ASPP1 is newly identified tumor suppressor, which has been proved both in transgenic mice model and in human cancers. 22, [32] [33] [34] The best known function of ASPP1 is through its direct interaction with nuclear p53 and activates transcriptional activities of p53 on the pro-apoptosis genes. 18, 35, 36 It is possible that loss of ASPP1 contributes to the inactivation of p53-dependent apoptosis and subsequent drug resistance in ccRCC cells harboring wild type p53. Since recent data from chemotherapy clinical trials suggested that capecitabine that is converted to metabolite 5-FU in cell is promising for RCC treatment, 5, 37 we test the above hypothesis in 5-FU treated cells. Based on the results obtained in our study, restoring ASPP1 in ccRCC cells indeed improves cells response to 5-FU by inducing apoptosis. Interestingly, ASPP1-induced better response to 5-FU is via activation of p53. First of all, Bcl-2 family members, such as Bcl-2 and Bax, are important downstream targets of p53 involved in p53-dependent apoptosis. We found that pro-apoptotic effector Bax and antiapoptotic Bcl-2 were both changed with restoring or silencing ASPP1 after 5-FU treatment. In addition, luciferase reporter of PIG-3, a reporter commonly used to examine p53's transcription activity toward apoptosis, was induced with 5-FU treatment, which was significantly elevated by ASPP1 expression and suppressed by ASPP1 silencing. Therefore, loss of ASPP1 in ccRCC at least in part contributes to the inactivation of pro-apoptotic functions of accumulated wild type p53 under stress. Rescue of ASPP1 is thus a potential strategy to improve ccRCC treatment efficiency by combined with either MDM2 inhibitor nutlin-3 or DNA damage chemotherapeutic drugs, both of which can stabilize p53 in the nucleus.
We also found in our study that CpG island promoter hypermethylation contributes to ASPP1 suppression both in vivo and in vitro. Nevertheless, 769-P cells are resistant to 5-Aza-2 0 dC treatment and no obvious promoter methylation was detected by BSP. Therefore, promoter methylation is one of mechanisms to inhibit ASPP1 expression in ccRCC, but not the only one. Previous cytogenetic studies and molecular genetic loss of heterozygosity (LOH) analysis have provided important insights into critical locus containing genes that might play vital roles in RCC development. 38 For instance, loss of 3q has been identified as the most commonly mutated region in ccRCC. Von Hippel-Lindau (VHL) localized at this region has been proved to be one of the most important tumor suppressors in ccRCC. Loss of 14q is the second most common chromosome alternations in RCC.
39 ASPP1 localized at 14q32.3. 22 Thus, LOH is a potential mechanism to suppress ASPP1 that is worthy of further investigation.
It is also worthy of note that loss of 14q is associated not only with oncogenesis but also with tumor progression. 40 This information suggested that important yet unidentified tumor suppressors resituated at 14q, whose inactivation is critical for the malignant phenotype of ccRCC. Previously, HIF-1a (14q23.2) has been identified as such a tumor suppressor and may confer to ccRCC development. 41 However, the HIF-1a's role in ccRCC remains controversial; both proand anti-cancer functions have been reported. 42 Here, downregulation of ASPP1, a gene located close to HIF-1, was found in a majority of ccRCC human specimens and cancer cell lines. Furthermore, loss of 14q in RCC is associated with high malignancy grade and poor survival. 40 In keep with it, decreased ASPP1 is negatively correlated with advanced stages and higher grade of ccRCC, suggesting that ASPP1 may be a prognostic marker for ccRCC. Supportively, by analyzing TCGA database, we found that ASPP1 suppression predicated a poorer survival of ccRCC patients. Moreover, it has been previously reported that chromosome arm 14q harbors important tumor suppressors in other cancer types, such as nasopharyngeal carcinoma, 43 esophageal carcinoma 44 and neuroblastoma. 45 It is worthy of further investigation whether ASPP1 is a tumor suppressor involved in the development of those cancers.
In summary, giving to the general downregulation of ASPP1 in ccRCC and its significant impact on cancer growth and drug resistance, further investigation is warranted to ascertain if ASPP1 could be a useful prognostic factor or therapeutic target in ccRCC and many others.
